Enlivex Therapeutics Shares Promising Results for Osteoarthritis

Enlivex Therapeutics Reports Positive Efficacy Data from Allocetra Trial

Nes-Ziona, Israel – Enlivex Therapeutics Ltd. (NASDAQ: ENLV) has announced encouraging interim results from its Phase I/II Allocetra™ trial focusing on patients with moderate to severe knee osteoarthritis. This randomized multi-country study marks a significant step forward in the company’s clinical journey.

Key Findings of the Allocetra™ Trial

The trial is structured in two stages. The initial Phase I stage was aimed at assessing the safety and tolerability of Allocetra™ administered directly into the affected knee joints. After successfully completing this phase, the company reported that no serious adverse effects were recorded during treatment.

Impressive Interim Results

The latest findings from three months post-treatment display statistically significant improvements in all critical efficacy endpoints. Among the patients evaluated, there was a marked decrease in average knee joint pain, dropping from 6.10 to 2.94, which indicates a 50% reduction. These results are not only promising but reflect the potential of Allocetra™ to enhance patients' quality of life significantly.

Patient Response Rates

A remarkable 83% of patients in the study experienced a pain reduction exceeding 40%, categorized as "responders" to the treatment. This contrasts with just 17% identified as non-responders, underscoring Allocetra™’s potential efficacy.

Functionality and Stiffness

Equally notable was the improvement in knee joint functionality, which improved from an average score of 4.7 pre-treatment to 2.8 at the three-month mark, indicating a 42% enhancement in functionality. Similarly, knee joint stiffness showed a significant decrease from 5.4 to 3.2, representing a 37% improvement. Both metrics demonstrate Allocetra™’s beneficial effect on joint mobility, which is critical for those suffering from osteoarthritis.

The Need for Innovative Solutions

Knee osteoarthritis poses a massive public health concern, significantly impacting individuals' daily lives. Affecting millions globally, it leads to chronic pain and severely limits mobility. Current treatment options have proven inadequate, and as highlighted by Einat Galamidi, MD, Medical Vice President of Enlivex, the need for effective therapeutics is increasingly urgent. As no approved medications effectively slow or reverse disease progression, Allocetra™ offers promising hope as a treatment alternative.

Phase II Trials Underway

Currently, the trial has transitioned into its Phase II stage, which will be double-blind, randomized, and placebo-controlled. This phase aims to enhance understanding of Allocetra™’s efficacy for knee osteoarthritis by examining its effects over a more extended period, including assessments at three, six, and 12 months post-treatment. The findings of this stage are anticipated to further solidify the therapeutic potential of Allocetra™ in managing knee osteoarthritis.

About Knee Osteoarthritis

Osteoarthritis stands as the most prevalent arthritis form, affecting millions across the United States and abroad. It is particularly prevalent among older adults, impacting around 40% of men and 47% of women during their lifetimes. As the population ages, the prevalence of osteoarthritis is projected to escalate significantly, urging researchers and companies like Enlivex to develop new solutions.

About Enlivex Therapeutics

Enlivex Therapeutics is at the forefront of macrophage reprogramming therapies aimed at treating severe diseases, currently focused on its product Allocetra™. This innovative therapy seeks to reestablish balance within the immune system, promising to address significant health challenges. Enlivex continues to push boundaries in the field of immunotherapy, underscoring its commitment to improving patient outcomes.

Frequently Asked Questions

What were the main results of the Allocetra trial?

The trial showed significant improvements in pain reduction and joint function in patients with knee osteoarthritis after treatment with Allocetra™, indicating a promising therapeutic effect.

How many patients were involved in the study?

The interim results were based on a total of 12 patients evaluated three months after receiving Allocetra™ injections.

What are the benefits of Allocetra™ over current treatments?

Allocetra™ offers a novel mechanism of action that may provide an alternative treatment for osteoarthritis, as current medications have not been shown to effectively halt or reverse disease progression.

When will the Phase II results be available?

The Phase II trial is currently ongoing, and results are expected in due course, with assessments scheduled at multiple intervals post-treatment.

How can I learn more about Enlivex Therapeutics?

To learn more about the company's initiatives and products, you can visit their official website or contact their investor relations directly.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.